[go: up one dir, main page]

MX2023012554A - Vacuna universal contra la gripe. - Google Patents

Vacuna universal contra la gripe.

Info

Publication number
MX2023012554A
MX2023012554A MX2023012554A MX2023012554A MX2023012554A MX 2023012554 A MX2023012554 A MX 2023012554A MX 2023012554 A MX2023012554 A MX 2023012554A MX 2023012554 A MX2023012554 A MX 2023012554A MX 2023012554 A MX2023012554 A MX 2023012554A
Authority
MX
Mexico
Prior art keywords
influenza
neuraminidase
infection
inducing
eliciting anti
Prior art date
Application number
MX2023012554A
Other languages
English (en)
Inventor
Ben Hause
Original Assignee
Cambridge Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Tech Llc filed Critical Cambridge Tech Llc
Publication of MX2023012554A publication Critical patent/MX2023012554A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones inmunogénicas para inducir una respuesta inmunitaria universal contra la gripe y, en particular, contra la gripe A, mediante la generación de anticuerpos anti-neuraminidasa que proporcionan protección contra la infección por gripe heteróloga. Composiciones que comprenden vectores de expresión de baculovirus recombinantes que expresan neuraminidasa en células de insecto cultivadas dispersas en un vehículo farmacéuticamente aceptable que comprende medios de cultivo de células de insecto y adyuvante opcional. Procedimientos de inducción de respuestas inmunitarias contra la gripe y, en particular, contra la gripe A, mediante la generación de anticuerpos anti-neuraminidasa en un animal huésped susceptible a la infección.
MX2023012554A 2018-12-12 2019-12-11 Vacuna universal contra la gripe. MX2023012554A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862778409P 2018-12-12 2018-12-12

Publications (1)

Publication Number Publication Date
MX2023012554A true MX2023012554A (es) 2023-11-08

Family

ID=68887227

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023012554A MX2023012554A (es) 2018-12-12 2019-12-11 Vacuna universal contra la gripe.
MX2019014943A MX2019014943A (es) 2018-12-12 2019-12-11 Vacuna universal contra la gripe.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014943A MX2019014943A (es) 2018-12-12 2019-12-11 Vacuna universal contra la gripe.

Country Status (6)

Country Link
US (3) US11351241B2 (es)
EP (1) EP3666286A1 (es)
JP (2) JP7107910B2 (es)
CA (1) CA3064760A1 (es)
MX (2) MX2023012554A (es)
WO (1) WO2020123757A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012554A (es) * 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
CA2180965C (en) 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US6103526A (en) * 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
ES2295175T3 (es) 2000-06-23 2008-04-16 Wyeth Holdings Corporation Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas.
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
CN101300023A (zh) * 2005-10-28 2008-11-05 贝林格尔·英格海姆维特梅迪卡有限公司 用于治疗/预防流感病原体在物种间传播的疫苗的用途
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
US7910112B2 (en) 2006-11-06 2011-03-22 Merial Limited Feline vaccines against avian influenza
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
WO2010125461A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
TWI411681B (zh) 2009-08-18 2013-10-11 Nat Univ Tsing Hua 桿狀病毒表現載體與其應用
JP5878126B2 (ja) 2009-11-13 2016-03-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 工学操作された微小胞を用いての直接的なタンパク質の送達
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CA2798151A1 (en) * 2010-05-07 2011-11-10 Camas Incorporated Immunogen adherence and method of making and using same
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
WO2014145287A2 (en) 2013-03-15 2014-09-18 University Of Maryland Swine influenza viruses and constructs and uses thereof
MX2017010908A (es) 2015-02-26 2017-12-07 Boehringer Ingelheim Vetmedica Gmbh Vacuna bivalente contra el virus de gripe porcina.
CN105457023B (zh) 2016-01-21 2019-10-08 重庆理工大学 一种预防用h9n2型流感病毒样颗粒疫苗及其制备方法
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
WO2019191261A1 (en) 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
MX2023012554A (es) * 2018-12-12 2023-11-08 Cambridge Tech Llc Vacuna universal contra la gripe.

Also Published As

Publication number Publication date
US11351241B2 (en) 2022-06-07
WO2020123757A1 (en) 2020-06-18
US20220296698A1 (en) 2022-09-22
US20240091336A1 (en) 2024-03-21
US20200188505A1 (en) 2020-06-18
MX2019014943A (es) 2020-08-06
US11771756B2 (en) 2023-10-03
EP3666286A1 (en) 2020-06-17
JP7107910B2 (ja) 2022-07-27
JP7491600B2 (ja) 2024-05-28
JP2022137177A (ja) 2022-09-21
US12102674B2 (en) 2024-10-01
CA3064760A1 (en) 2020-06-12
JP2020094054A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
AR090401A1 (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos
WO2015142671A3 (en) Influenza virus vectors and uses therefor
NZ708065A (en) Novel mucosal adjuvants and delivery systems
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
PH12015502353A1 (en) Fusion polypeptides and vaccines
MX2017011322A (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
BR112018069079A2 (pt) construtos de alfavírus vivos atenuados e métodos e usos dos mesmos
MX382530B (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
BR112012008861A2 (pt) parvovírus, vacina, ácido nucleico isolado, composição imunogênica, método para provocar uma resposta imune em um animal contra a infecção por parvovírus, proteína vp-2 de parvovírus purificada, vetor de expressão, e método para exterminar células tumorais em um mamífero.
MX2019014943A (es) Vacuna universal contra la gripe.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
BR112014014390A2 (pt) levedura recombinante, seus usos, processo para vacinação, oligonucleotídeo, vetor de expressão, e método de produção de uma composição de vacina
Murugan et al. Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
RU2012107170A (ru) Способ получения чумных вакцин
CL2017002196A1 (es) Vacuna recombinante contra enteropatía proliferativa en animales.
BR112018075585A2 (pt) spv recombinante multivalente
Qin et al. Biological characteristics and immunological properties in Muscovy ducks of H5N6 virus-like particles composed of HA-TM/HA-TMH3 and M1
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.